About Arcellx, Inc.
https://arcellx.comArcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
CEO
Rami Elghandour
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 164
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
GILEAD SCIENCES, INC.
Shares:6.72M
Value:$469.52M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:6.35M
Value:$443.78M
FMR LLC
Shares:5.76M
Value:$402.49M
Summary
Showing Top 3 of 223
About Arcellx, Inc.
https://arcellx.comArcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM).
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $4.95M ▼ | $31.64M ▼ | $-55.78M ▼ | -1.13K% ▼ | $-0.99 ▼ | $-53.94M ▼ |
| Q2-2025 | $7.55M ▼ | $66.28M ▼ | $-52.77M ▲ | -698.58% ▲ | $-0.94 ▲ | $-51.12M ▲ |
| Q1-2025 | $8.13M ▼ | $77.03M ▲ | $-62.27M ▼ | -766.02% ▼ | $-1.13 ▼ | $-60.68M ▼ |
| Q4-2024 | $15.27M ▼ | $68.42M ▲ | $-47.08M ▼ | -308.4% ▼ | $-0.88 ▼ | $-43.78M ▼ |
| Q3-2024 | $26.03M | $59.65M | $-25.87M | -99.37% | $-0.48 | $-24.2M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $461.38M ▲ | $655.92M ▲ | $215.14M ▼ | $440.78M ▲ |
| Q2-2025 | $453.1M ▼ | $619.09M ▼ | $226.86M ▼ | $392.22M ▼ |
| Q1-2025 | $543.26M ▼ | $648.08M ▼ | $231.18M ▼ | $416.91M ▼ |
| Q4-2024 | $587.38M ▲ | $711.33M ▼ | $256.54M ▼ | $454.79M ▼ |
| Q3-2024 | $574.25M | $764.91M | $281.89M | $483.02M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-55.78M ▼ | $-49.21M ▼ | $-20.03M ▼ | $86.1M ▲ | $16.87M ▲ | $-49.5M ▼ |
| Q2-2025 | $-52.77M ▲ | $-39.73M ▲ | $10.74M ▼ | $10.26M ▲ | $-18.73M ▲ | $-40.22M ▲ |
| Q1-2025 | $-62.27M ▼ | $-63.15M ▼ | $37.78M ▲ | $543K ▲ | $-24.82M ▲ | $-63.92M ▼ |
| Q4-2024 | $-47.08M ▼ | $-46.03M ▼ | $-4.12M ▼ | $-6.02M ▼ | $-56.17M ▼ | $-47.53M ▼ |
| Q3-2024 | $-25.87M | $30.72M | $35.76M | $-4.66M | $61.82M | $28.43M |
CEO
Rami Elghandour
Compensation Summary
(Year 2024)
ETFs Holding This Stock
Summary
Showing Top 3 of 164
Ratings Snapshot
Rating : C
Most Recent Analyst Grades
Grade Summary
Showing Top 4 of 4
Price Target
Institutional Ownership
GILEAD SCIENCES, INC.
Shares:6.72M
Value:$469.52M
T. ROWE PRICE INVESTMENT MANAGEMENT, INC.
Shares:6.35M
Value:$443.78M
FMR LLC
Shares:5.76M
Value:$402.49M
Summary
Showing Top 3 of 223